GLP-1 RA may lower the risk of CVD mortality and all-cause mortality in patients with established CVD, according to meta-analyses of moderate- to high-certainty evidence; moderate-certainty evidence is probable in favor of using GLP-1 RA to lower fatal and non-fatal stroke. The gene discussed is GLP1R; the disease is stroke disorder.